| Andrew Thomas Guertler, MD | |
|
724 South Mason Street Msc 7901 Jmu Health Center, Harrisonburg, VA 22807-0001 | |
| (540) 568-6178 | |
| (540) 568-6176 |
| Full Name | Andrew Thomas Guertler |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 724 South Mason Street Msc 7901 Jmu Health Center, Harrisonburg, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023181005 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101040646 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Thomas Guertler, MD 724 South Mason St, Msc 7901, James Madison University Health Center, Harrisonburg, VA 22807 Ph: (540) 568-6178 | Andrew Thomas Guertler, MD 724 South Mason Street Msc 7901 Jmu Health Center, Harrisonburg, VA 22807-0001 Ph: (540) 568-6178 |
News Archive
New research, published today in The Lancet, highlights important information for health professionals and parents about the factors which may increase the likelihood of a baby being born with a birth defect.
A new study focused on the chronological changes in humoral and cell-mediated immune responses, during and after the BNT162b2 vaccine administration, among hospital workers of a national medical institution in Japan.
The first study to look extensively at sexual function in women who underwent bariatric surgery found that significant improvements in overall sexual function, most reproductive hormones and in psychological status were maintained over two years following surgery.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
› Verified 6 days ago
Nazir A Adam, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 235 Cantrell Ave, Harrisonburg, VA 22801 Phone: 540-433-4100 | |
Christina Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2010 Health Campus Dr, Harrisonburg, VA 22801 Phone: 540-689-1414 | |
John J Coakley, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 235 Cantrell Ave, Harrisonburg, VA 22801 Phone: 540-433-4100 | |
Tomer Feldman, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 235 Cantrell Ave, Harrisonburg, VA 22801 Phone: 540-433-4100 | |
Michael Ilagan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 253 Cantrell Ave, Harrisonburg, VA 22801 Phone: 540-433-4100 | |
Abby J Massey, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 724 S Mason St, Msc 7901, Harrisonburg, VA 22807 Phone: 540-568-3965 |